Clinical Overview
Amoxycillin (Amoxicillin) is a semisynthetic aminopenicillin bactericidal antibiotic. It acts by inhibiting the cross-linking of bacterial peptidoglycan chains in the bacterial cell wall via binding to penicillin-binding proteins (PBPs), leading to autolysis and bacterial cell death. Indicated for uncomplicated ear, nose, and throat infections (streptococcal pharyngitis, acute otitis media), lower respiratory infections, uncomplicated urinary tract infections, and Helicobacter pylori eradication (in combination regimens).
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Reconstitute the dry powder with fresh boiled and cooled water up to the indicated fill mark. Shake well before each use. Measure precisely with the syringe or dosing cup provided. Can be given with or without feeds. Keep refrigerated and discard after 7-14 days.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Mild diarrhea, nausea, vomiting, skin rash, and oral candidiasis. Rare/Severe: Anaphylaxis, Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN), crystalluria, and pseudomembranous colitis.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Contraindicated in individuals with documented penicillin hypersensitivity. High risk of erythematous maculopapular rash if administered to patients with infectious mononucleosis (glandular fever) or lymphocytic leukemia. Dosage reduction required in severe renal impairment.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified pharmacist before initiating, modifying, or substituting any medication regimen.
Amoxycillin 1g + Potassium Clavulanate 200mg Injection
Amoxycillin and Potassium Clavulanate is a synergistic broad-spectrum antibacterial combination. Amoxycillin, an extended-spectrum aminopenicillin, inhibits bacterial cell wall peptidoglycan synthesis, while clavulanic acid, a beta-lactamase inhibitor, competitively binds and inactivates beta-lactamase enzymes produced by resistant bacteria, thereby safeguarding amoxycillin from enzymatic degradation. Indicated for acute otitis media, bacterial sinusitis, community-acquired pneumonia, skin and skin structure infections, recurrent urinary tract infections, and post-operative dental and surgical infections.
Amoxycillin 200mg + Potassium Clavulanate 28.5mg Oral Suspension per 5ml
Amoxycillin and Potassium Clavulanate is a synergistic broad-spectrum antibacterial combination. Amoxycillin, an extended-spectrum aminopenicillin, inhibits bacterial cell wall peptidoglycan synthesis, while clavulanic acid, a beta-lactamase inhibitor, competitively binds and inactivates beta-lactamase enzymes produced by resistant bacteria, thereby safeguarding amoxycillin from enzymatic degradation. Indicated for acute otitis media, bacterial sinusitis, community-acquired pneumonia, skin and skin structure infections, recurrent urinary tract infections, and post-operative dental and surgical infections.
Amoxycillin 250mg + Potassium Clavulanate 50mg Injection
Amoxycillin and Potassium Clavulanate is a synergistic broad-spectrum antibacterial combination. Amoxycillin, an extended-spectrum aminopenicillin, inhibits bacterial cell wall peptidoglycan synthesis, while clavulanic acid, a beta-lactamase inhibitor, competitively binds and inactivates beta-lactamase enzymes produced by resistant bacteria, thereby safeguarding amoxycillin from enzymatic degradation. Indicated for acute otitis media, bacterial sinusitis, community-acquired pneumonia, skin and skin structure infections, recurrent urinary tract infections, and post-operative dental and surgical infections.
Amoxycillin 500mg + Potassium Clavulanate 100mg Injection
Amoxycillin and Potassium Clavulanate is a synergistic broad-spectrum antibacterial combination. Amoxycillin, an extended-spectrum aminopenicillin, inhibits bacterial cell wall peptidoglycan synthesis, while clavulanic acid, a beta-lactamase inhibitor, competitively binds and inactivates beta-lactamase enzymes produced by resistant bacteria, thereby safeguarding amoxycillin from enzymatic degradation. Indicated for acute otitis media, bacterial sinusitis, community-acquired pneumonia, skin and skin structure infections, recurrent urinary tract infections, and post-operative dental and surgical infections.